EXEL (Exelixis Inc)
Insider Trading Activity
Every open-market purchase and sale reported by EXEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Mary C Beckerle | Director | Sell | — | — |
| 2026-06-03 | Sue Gail Eckhardt | Director | Sell | — | — |
| 2026-06-03 | JACK L WYSZOMIERSKI | Director | Sell | — | — |
| 2026-05-29 | DAVID EDWARD JOHNSON | Director | A | — | — |
| 2026-05-29 | GEORGE POSTE | Director | A | — | — |
| 2026-05-29 | JACK L WYSZOMIERSKI | Director | A | — | — |
| 2026-05-29 | Bob Oliver | Director | A | — | — |
| 2026-05-29 | Mary C Beckerle | Director | A | — | — |
| 2026-05-29 | Maria C Freire | Director | A | — | — |
| 2026-05-29 | Julie Smith | Director | A | — | — |
| 2026-05-29 | Sue Gail Eckhardt | Director | A | — | — |
| 2026-05-29 | Tomas J. Heyman | Director | A | — | — |
| 2026-05-29 | STELIOS PAPADOPOULOS | Director | A | — | — |
| 2026-05-28 | Dana Aftab | EVP, Research and Development | Sell | — | — |
| 2026-05-22 | Patrick J. Haley | EVP, Commercial | Sell | — | — |
| 2026-05-19 | Dana Aftab | EVP, Research and Development | F | — | — |
| 2026-05-19 | Brenda Hefti | SVP and General Counsel | MIXED | — | — |
| 2026-05-19 | Patrick J. Haley | EVP, Commercial | F | — | — |
| 2026-05-19 | Christopher J. Senner | EVP and CFO | MIXED | — | — |
| 2026-05-19 | MICHAEL MORRISSEY | President and CEO | MIXED | — | — |
| 2026-05-08 | MICHAEL MORRISSEY | President and CEO | G | — | — |
| 2026-05-08 | GEORGE POSTE | Director | Sell | — | — |
| 2026-05-08 | Maria C Freire | Director | MIXED | — | — |
| 2026-05-08 | Mary C Beckerle | Director | MIXED | — | — |
| 2026-03-02 | MICHAEL MORRISSEY | President and CEO | MIXED | — | — |
| 2026-03-02 | Patrick J. Haley | EVP, Commercial | A | — | — |
| 2026-03-02 | Brenda Hefti | SVP and General Counsel | A | — | — |
| 2026-03-02 | Christopher J. Senner | EVP and CFO | A | — | — |
| 2026-03-02 | Dana Aftab | EVP, Research and Development | A | — | — |
| 2026-02-26 | Dana Aftab | EVP, Research and Development | Sell | — | — |
| 2026-02-23 | Dana Aftab | EVP, Research and Development | Sell | — | — |
| 2026-02-20 | JACK L WYSZOMIERSKI | Director | MIXED | — | — |
| 2026-02-19 | Julie Smith | Director | MIXED | — | — |
| 2026-02-18 | Brenda Hefti | SVP and General Counsel | MIXED | — | — |
| 2026-02-18 | Bob Oliver | Director | MIXED | — | — |
| 2026-02-18 | Dana Aftab | EVP, Research and Development | F | — | — |
| 2026-02-18 | Sue Gail Eckhardt | Director | Sell | — | — |
| 2026-02-18 | MICHAEL MORRISSEY | President and CEO | MIXED | — | — |
| 2026-02-18 | Patrick J. Haley | EVP, Commercial | MIXED | — | — |
| 2026-02-18 | Christopher J. Senner | EVP and CFO | MIXED | — | — |
| 2026-01-16 | Christopher J. Senner | EVP and CFO | MIXED | — | — |
| 2026-01-16 | Patrick J. Haley | EVP, Commercial | MIXED | — | — |
| 2026-01-16 | Dana Aftab | EVP, Research and Development | MIXED | — | — |
| 2026-01-16 | MICHAEL MORRISSEY | President and CEO | MIXED | — | — |
| 2025-12-05 | Brenda Hefti | SVP and General Counsel | A | — | — |
| 2025-11-26 | DAVID EDWARD JOHNSON | Director | Buy | — | — |
| 2025-11-24 | Dana Aftab | EVP, Research and Development | G | — | — |
| 2025-11-24 | Patrick J. Haley | EVP, Commercial | Sell | — | — |
| 2025-11-19 | Bob Oliver | Director | G | — | — |
| 2025-11-13 | Mary C Beckerle | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 3,366,335 | — |
| — | Director | 1,571,438 | — |
| — | Director | 1,197,595 | — |
| — | EVP and CFO | 989,941 | — |
| — | Director | 928,906 | — |
| — | Director | 723,680 | — |
| — | EVP & General Counsel | 719,395 | — |
| — | Pres, Prod Dev & Med Aff & CMO | 703,958 | — |
| — | EVP, Research and Development | 600,576 | — |
| — | EVP Prod Dev & Med Aff & CMO | 538,169 | — |
| — | EVP, Scientific Strategy & CSO | 428,063 | — |
| — | Director | 424,415 | — |
| — | EVP, Commercial | 357,638 | — |
| — | EVP, Prod Dev & Med Aff &CMO | 307,654 | — |
| — | Director | 284,384 | — |
| — | Director | 221,375 | — |
| — | Director | 127,199 | — |
| — | SVP and General Counsel | 118,914 | — |
| — | Director | 109,186 | — |
| — | EVP and CFO | 99,430 | — |
| — | Director | 93,989 | — |
| — | Director | 58,701 | — |
| — | Director | 51,756 | — |
| — | Director | 50,649 | — |
| — | Director | 35,703 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EXEL quote page; the site-wide leaderboard is on the insider transactions hub.